Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers

Abstract

Background: A new treatment for actinic keratoses, ingenol mebutate, was recently approved by the US Food and Drug Administration.

Objective: To review the mechanisms of action, efficacy and safety data, and practical recommendations for ingenol mebutate.

Methods: The PubMed and clinicaltrials.gov databases were searched in March/April 2012 using the terms PEP005, ingenol mebutate, and ingenol 3-angelate. The abstracts from the Annual Scientific Meeting of the Australian College of Dermatologists (2009-2011) and the Annual Meeting of the American Academy of Dermatology (2009-2012) were also searched.

Results: Due to its multiple mechanisms of action, ingenol mebutate treatment resulted in short- and long-term efficacy similar to other topical treatments for actinic keratoses in a shorter period of 2 or 3 days. This short therapy would reduce the duration of adverse events. Premarketing trials for treatment of nonmelanoma skin cancers also showed promising results for ingenol mebutate.

Conclusion: Ingenol mebutate is a convenient, safe, and effective intervention for precancerous and cancerous skin conditions.